Diagnostic algorithm for lower-risk myelodysplastic syndromes

Ghulam J. Mufti, Donal P. McLornan, Arjan A. van de Loosdrecht, Ulrich Germing, Robert P. Hasserjian

Research output: Contribution to journalReview articleAcademicpeer-review

Abstract

Rapid advances over the past decade have uncovered the heterogeneous genomic and immunologic landscape of myelodysplastic syndromes (MDS). This has led to notable improvements in the accuracy and timing of diagnosis and prognostication of MDS, as well as the identification of possible novel targets for therapeutic intervention. For the practicing clinician, however, this increase in genomic, epigenomic, and immunologic knowledge needs consideration in a “real-world” context to aid diagnostic specificity. Although the 2016 revision to the World Health Organization classification for MDS is comprehensive and timely, certain limitations still exist for day-to-day clinical practice. In this review, we describe an up-to-date diagnostic approach to patients with suspected lower-risk MDS, including hypoplastic MDS, and demonstrate the requirement for an “integrated” diagnostic approach. Moreover, in the era of rapid access to massive parallel sequencing platforms for mutational screening, we suggest which patients should undergo such analyses, when such screening should be performed, and how those data should be interpreted. This is particularly relevant given the recent findings describing age-related clonal hematopoiesis.
Original languageEnglish
Pages (from-to)1679-1696
JournalLeukemia
Volume32
Issue number8
DOIs
Publication statusPublished - 2018

Cite this

Mufti, G. J., McLornan, D. P., van de Loosdrecht, A. A., Germing, U., & Hasserjian, R. P. (2018). Diagnostic algorithm for lower-risk myelodysplastic syndromes. Leukemia, 32(8), 1679-1696. https://doi.org/10.1038/s41375-018-0173-2
Mufti, Ghulam J. ; McLornan, Donal P. ; van de Loosdrecht, Arjan A. ; Germing, Ulrich ; Hasserjian, Robert P. / Diagnostic algorithm for lower-risk myelodysplastic syndromes. In: Leukemia. 2018 ; Vol. 32, No. 8. pp. 1679-1696.
@article{d246f0947c1e4209b58ba21597043d4b,
title = "Diagnostic algorithm for lower-risk myelodysplastic syndromes",
abstract = "Rapid advances over the past decade have uncovered the heterogeneous genomic and immunologic landscape of myelodysplastic syndromes (MDS). This has led to notable improvements in the accuracy and timing of diagnosis and prognostication of MDS, as well as the identification of possible novel targets for therapeutic intervention. For the practicing clinician, however, this increase in genomic, epigenomic, and immunologic knowledge needs consideration in a “real-world” context to aid diagnostic specificity. Although the 2016 revision to the World Health Organization classification for MDS is comprehensive and timely, certain limitations still exist for day-to-day clinical practice. In this review, we describe an up-to-date diagnostic approach to patients with suspected lower-risk MDS, including hypoplastic MDS, and demonstrate the requirement for an “integrated” diagnostic approach. Moreover, in the era of rapid access to massive parallel sequencing platforms for mutational screening, we suggest which patients should undergo such analyses, when such screening should be performed, and how those data should be interpreted. This is particularly relevant given the recent findings describing age-related clonal hematopoiesis.",
author = "Mufti, {Ghulam J.} and McLornan, {Donal P.} and {van de Loosdrecht}, {Arjan A.} and Ulrich Germing and Hasserjian, {Robert P.}",
year = "2018",
doi = "10.1038/s41375-018-0173-2",
language = "English",
volume = "32",
pages = "1679--1696",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "8",

}

Mufti, GJ, McLornan, DP, van de Loosdrecht, AA, Germing, U & Hasserjian, RP 2018, 'Diagnostic algorithm for lower-risk myelodysplastic syndromes' Leukemia, vol. 32, no. 8, pp. 1679-1696. https://doi.org/10.1038/s41375-018-0173-2

Diagnostic algorithm for lower-risk myelodysplastic syndromes. / Mufti, Ghulam J.; McLornan, Donal P.; van de Loosdrecht, Arjan A.; Germing, Ulrich; Hasserjian, Robert P.

In: Leukemia, Vol. 32, No. 8, 2018, p. 1679-1696.

Research output: Contribution to journalReview articleAcademicpeer-review

TY - JOUR

T1 - Diagnostic algorithm for lower-risk myelodysplastic syndromes

AU - Mufti, Ghulam J.

AU - McLornan, Donal P.

AU - van de Loosdrecht, Arjan A.

AU - Germing, Ulrich

AU - Hasserjian, Robert P.

PY - 2018

Y1 - 2018

N2 - Rapid advances over the past decade have uncovered the heterogeneous genomic and immunologic landscape of myelodysplastic syndromes (MDS). This has led to notable improvements in the accuracy and timing of diagnosis and prognostication of MDS, as well as the identification of possible novel targets for therapeutic intervention. For the practicing clinician, however, this increase in genomic, epigenomic, and immunologic knowledge needs consideration in a “real-world” context to aid diagnostic specificity. Although the 2016 revision to the World Health Organization classification for MDS is comprehensive and timely, certain limitations still exist for day-to-day clinical practice. In this review, we describe an up-to-date diagnostic approach to patients with suspected lower-risk MDS, including hypoplastic MDS, and demonstrate the requirement for an “integrated” diagnostic approach. Moreover, in the era of rapid access to massive parallel sequencing platforms for mutational screening, we suggest which patients should undergo such analyses, when such screening should be performed, and how those data should be interpreted. This is particularly relevant given the recent findings describing age-related clonal hematopoiesis.

AB - Rapid advances over the past decade have uncovered the heterogeneous genomic and immunologic landscape of myelodysplastic syndromes (MDS). This has led to notable improvements in the accuracy and timing of diagnosis and prognostication of MDS, as well as the identification of possible novel targets for therapeutic intervention. For the practicing clinician, however, this increase in genomic, epigenomic, and immunologic knowledge needs consideration in a “real-world” context to aid diagnostic specificity. Although the 2016 revision to the World Health Organization classification for MDS is comprehensive and timely, certain limitations still exist for day-to-day clinical practice. In this review, we describe an up-to-date diagnostic approach to patients with suspected lower-risk MDS, including hypoplastic MDS, and demonstrate the requirement for an “integrated” diagnostic approach. Moreover, in the era of rapid access to massive parallel sequencing platforms for mutational screening, we suggest which patients should undergo such analyses, when such screening should be performed, and how those data should be interpreted. This is particularly relevant given the recent findings describing age-related clonal hematopoiesis.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85049114077&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/29946191

U2 - 10.1038/s41375-018-0173-2

DO - 10.1038/s41375-018-0173-2

M3 - Review article

VL - 32

SP - 1679

EP - 1696

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 8

ER -